blog
FDA enforcement analysis
Sourced, dated analysis for compliance and regulatory affairs teams.
2026-07-22
FDA's New Pre-Approval Inspection Rules: An 8-Point Readiness Checklist
FDA revised Compliance Program 7346.832 on June 29, 2026, effective August 10, 2026 — a risk-based model that now decides whether a Pre-Approval Inspection happens at all, and how deep it goes.
Read more →2026-07-17
What Does a 0.016 PPM Drug Residue Overage Cost a Dairy Farm?
FDA's Center for Veterinary Medicine cited Allandale Dairy after a slaughtered cow's liver tissue tested at 0.116 ppm sulfadimethoxine, over the 0.1 ppm tolerance, plus extralabel dosing that didn't match the label or the vet's prescription — this database's first CVM case.
Read more →2026-07-17
What's the Difference Between FDA Debarment and a Warning Letter?
Debarment bars a specific person or company from the drug-approval process after a felony conviction. A Warning Letter cites violations at a company, no conviction required. A February 2026 order shows the split in practice.
Read more →2026-07-17
How Do FDA Warning Letters Differ Between Drugs and Devices? CDER and CDRH Compared for 2026
FDA issued 695 warning letters in 2025 — only 8% targeted devices, while CDER's own count rose 50% in FY2025. A structural comparison plus two 2026 case studies: Spa De Soleil (CDER) and ZIIP, Inc. (CDRH).
Read more →2026-07-16
Does Amazon Own the Liability When FBA Ships an Unapproved Drug?
FDA cited Amazon.com, Inc. directly, not a third-party seller, after Fulfillment by Amazon shipped three unapproved drugs with disease-treatment claims for phimosis and balanitis. No public response or close-out has been posted yet.
Read more →2026-07-16
What Is an FDA Field Alert Report? The Three-Working-Day Deadline Explained
A FAR is due 3 working days after an NDA/ANDA holder learns of certain distributed-product quality problems, under 21 CFR 314.81(b)(1). A September 2025 warning letter to Somerset Therapeutics shows what a four-month-late report costs.
Read more →2026-07-16
When Does a Dietary Supplement Become an "Unapproved New Drug" to FDA?
FDA's March 2026 warning letter to Nupack Inc. cited one supplement line as an unapproved drug, misbranded, and adulterated at once. The claim types that cross the disease-claim line, and the CGMP gaps FDA layers on top.
Read more →2026-07-15
Why Did FDA Reject BlephEx's Quality Fixes Six Times?
CDRH cited BlephEx, LLC for marketing three ophthalmic devices beyond their cleared use, an unreported charger correction after a handpiece "blew up," and seven Quality System Regulation violations — one a repeat of a 2019 citation. FDA rejected six company responses in a row.
Read more →2026-07-15
What's the Difference Between an FDA Recall and a Warning Letter?
A recall pulls a specific product from the market; a Warning Letter cites the practices behind it. Most recalls are voluntary under 21 CFR Part 7 — FDA's mandatory recall authority is narrow and product-specific.
Read more →2026-07-15
How do you build a CGMP data integrity remediation plan FDA will actually accept?
Data integrity has topped FDA's CGMP citation list for over two decades. A 7-step build order for a remediation plan, from the 2018 FDA Q&A guidance to the June 2026 Huons Co. warning letter.
Read more →2026-07-14
Happiest Baby FDA Warning Letter 718306 — SNOO Sleep Sack sizing violations
CDRH cited the SNOO Smart Sleeper maker for adulteration and misbranding after finding unauthorized sleep sack sizes, including an X-Small for 4-8 lb infants, outside the three sizes cleared under its De Novo authorization.
Read more →2026-07-14
What Are the Six Rungs of FDA's Enforcement Escalation Ladder?
A Warning Letter is rung two of six, not FDA's worst move. The full ladder — Untitled Letter, Warning Letter, Import Alert/DWPE, seizure, injunction, and consent decree — ranked with the statutory basis for each.
Read more →2026-07-14
Why is FDA sending cosmetics companies CGMP warning letters before its cosmetic GMP rule even exists?
At least five cosmetics-labeled facilities got FDA CGMP warning letters between November 2025 and April 2026, all cited under existing 21 CFR 210/211 drug rules — the missing MoCRA GMP rule was never a compliance grace period.
Read more →2026-07-13
What Is CGMP? FDA's Core Manufacturing Standard, Explained
CGMP isn't a certification a company earns once — it's re-checked at every FDA inspection. Where the requirements live in 21 CFR Parts 210, 211, 212, and 600, and how to read a Warning Letter's CFR citations.
Read more →2026-07-13
Why did FDA cite nine OTC drug manufacturers on three continents the same day?
On June 2, 2026, FDA issued 9 CGMP warning letters to OTC drug makers in 7 countries — 60% of that month's CGMP letters in a single batch. The shared citations, and what they mean for OTC manufacturers and private-label brands.
Read more →2026-07-12
What is an FDA Warning Letter Close-Out Letter?
It confirms one Warning Letter's citations were corrected — it doesn't retract the letter, and most corrected Warning Letters never get one at all. How the close-out process actually works, and why a missing letter isn't an open compliance flag.
Read more →2026-07-12
Is FDA's new device quality rule a compliance reset? The first warning letters say no
FDA's QMSR replaced most of 21 CFR 820 on Feb 2, 2026. A March 2026 warning letter to Medline Industries cites a QS-Regulation-era inspection and still demands a QMSR-standard fix — no grace period.
Read more →2026-07-11
Can FDA order a drug maker to never restart production?
FDA cited New Life Pharma for selling unapproved semaglutide and tirzepatide vials, zero aseptic validation, and denying inspectors access to two rooms labeled "Area Not in Use" — then told the firm not to restart manufacturing at all.
Read more →2026-07-11
What is an FDA consent decree, and how does a Warning Letter lead to one?
Pharmasol Corporation went from a 2019 Warning Letter to a December 2023 consent decree over the same unresolved CGMP failures. The step-by-step timeline from inspection to court order, and who pays once a decree is entered.
Read more →2026-07-11
Why did FDA send 13 warning letters to online ketamine sellers in a single day?
One day, one drug, 13 letters — 42% of FDA's 2026 unapproved-drug warning letters. The shared statutory pattern, the MARCS numbering that reveals a single drafting batch, and what it means for telehealth and DTC drug sellers.
Read more →2026-07-10
What's the difference between an FDA Untitled Letter and a Warning Letter?
Only one of these two FDA advisory actions contains the sentence that makes it a legal threat. How the two-tier system works, and what each one means for a compliance risk register.
Read more →2026-07-10
What actually makes an FDA warning letter response "adequate" enough to close out?
Wizcure Pharmaa suspended manufacturing, hired a consultant, and still got rejected on all four citations. An 8-point adequacy checklist built directly from FDA's own Regulatory Procedures Manual.
Read more →2026-07-09
Sato Pharmaceutical Co., Ltd. FDA Warning Letter 320-26-75 — aseptic filling CGMP violations
CDER called the firm's ISO 5 aseptic filling line "fundamentally unsuitable" after six media fill failures, plus an inadequate stability program and OTC products released without required microbiological testing — FDA rejected the response on all three citations.
Read more →2026-07-09
How to read your FDA inspection classification: NAI vs. VAI vs. OAI
A Form 483 is not your classification. Five steps to figure out where your last FDA inspection actually landed, and what OAI does (and doesn’t) mean for what happens next.
Read more →2026-07-09
Can you blame an AI agent for a CGMP violation? FDA just answered that.
FDA’s April 2, 2026 warning letter to Purolea Cosmetics Lab cites unreviewed AI-generated specifications and procedures — the first warning letter with a standalone AI-misuse section, tied to 21 CFR 211.22(c).
Read more →2026-07-08
Huons Co., Ltd. FDA Warning Letter 320-26-95 — data integrity CGMP violations
A microbiology team leader cut finished pages out of a lab logbook with a knife and replaced them with fabricated ones. FDA also found 1,897 blank uncontrolled forms and rejected the firm's CAPA plan after it withheld a promised third-party audit report.
Read more →2026-07-08
What is an FDA Import Alert, and what does DWPE mean?
FDA can detain shipments at the border without testing them, once a firm appears on an Import Alert under the FD&C Act's appearance standard. How the Red/Yellow/Green lists work, who carries the burden of proof, and how removal works.
Read more →2026-07-08
The 5 most-cited FDA warning letter violations in FY2025, ranked
21 CFR 211.22 topped the list, cited in 62 of 134 inspection-based warning letters. The full ranked breakdown of what FDA cited most, and what each citation means for a quality system.
Read more →2026-07-07
Wizcure Pharmaa FDA Warning Letter 320-26-97 — sterile CGMP violations
"Original plates were discarded and replaced with new plates." CDER cited the Bhiwadi, India sterile manufacturer for a fabricated microbial-plate result, a missing ISO 5/ISO 7 barrier, deficient media fills, and rusted aseptic equipment — FDA found the response inadequate on all four citations.
Read more →2026-07-07
What's the difference between a Form 483 and an FDA Warning Letter?
A Form 483 is a field-issued inspection note. A Warning Letter is a later, headquarters-reviewed legal notice. Why most 483s never escalate, and why Warning Letter counts alone understate FDA enforcement activity.
Read more →2026-07-07
FDA proposes to exclude semaglutide and tirzepatide from the 503B Bulks List
FDA's April 30, 2026 proposal would permanently bar 503B outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk API. The comment period closed June 29 with 4,000+ submissions — here's the clinical-need standard behind it.
Read more →2026-07-06
Genzyme Ireland Limited FDA Warning Letter CBER 26-728681 — biologics CGMP violations
CBER cited the Sanofi subsidiary for a quality control unit that failed to enforce CGMP, incomplete lab records including (b)(4) tests repeated up to 11 times undocumented, and deviations cancelled without root-cause investigation.
Read more →2026-07-06
Why did the FDA send Novo Nordisk a warning letter over Ozempic and Wegovy safety reporting?
FDA's March 5, 2026 warning letter names specific Argus case numbers — a stroke, a suicide, and unreported deaths — where Novo Nordisk's own procedures blocked required 15-day adverse event reports.
Read more →2026-07-06
FDA's Quality Management Maturity program, explained
FDA opened the third year of its voluntary QMM assessment on February 11, 2026. Only firms already rated No Action Indicated or Voluntary Action Indicated can apply — here is what gets scored, and the FOIA risk law firms are flagging.
Read more →2026-07-05
Pharmathen International FDA Warning Letter 320-26-80 — sterile injectable CGMP violations
CDER cited Pharmathen International S.A., Evrou, Greece, for failed airflow studies, inadequate failure investigations, and undocumented lab records — the firm suspended manufacturing and its customers recalled affected batches.
Read more →2026-07-05
What triggers an FDA Warning Letter for compounded GLP-1 marketing?
Three enforcement waves and one legal theory: marketing that implies a compounded semaglutide or tirzepatide product is FDA-approved. The exact phrases flagged, and an 8-step audit for marketing and compliance teams.
Read more →2026-07-05
How long does a company have to respond to an FDA Warning Letter?
Usually 15 working days — a norm from FDA’s Regulatory Procedures Manual, not a statute. How the clock works, how it differs from the Form 483 window, and what the March 2026 draft guidance changed.
Read more →2026-07-04
Excelvision (Fareva) FDA Warning Letter 726714 — sterile ophthalmic CGMP violations
CDER cited Excelvision (Fareva), Annonay, France, for microbial-contamination and facility failures on a sterile eye-drop line, a repeat violation now under Import Alert 66-40.
Read more →2026-07-02
Why FDA enforcement is up nearly 60% in 2026 — and what it means for your compliance team
FDA issued 303 drug Warning Letters in FY2025, up 59% from FY2024. What is driving the increase, and five practical implications for compliance teams.
Read more →